| Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes E Setiawan, AA Wilson, R Mizrahi, PM Rusjan, L Miler, G Rajkowska, ... JAMA psychiatry 72 (3), 268-275, 2015 | 858 | 2015 |
| Increased stress-induced dopamine release in psychosis R Mizrahi, J Addington, PM Rusjan, I Suridjan, A Ng, I Boileau, ... Biological psychiatry 71 (6), 561-567, 2012 | 307 | 2012 |
| Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum AL Benedet, M Milà-Alomà, A Vrillon, NJ Ashton, TA Pascoal, F Lussier, ... JAMA neurology 78 (12), 1471-1483, 2021 | 230 | 2021 |
| Imaging Neuroinflammation in Gray and White Matter in Schizophrenia: An In-Vivo PET Study With [ 18 F]-FEPPA M Kenk, T Selvanathan, N Rao, I Suridjan, P Rusjan, G Remington, ... Schizophrenia bulletin 41 (1), 85-93, 2015 | 186 | 2015 |
| Translocator Protein (18 kDa) Polymorphism (rs6971) Explains in-vivo Brain Binding Affinity of the PET Radioligand [18F]-FEPPA R Mizrahi, PM Rusjan, J Kennedy, B Pollock, B Mulsant, I Suridjan, ... Journal of Cerebral Blood Flow & Metabolism 32 (6), 968-972, 2012 | 160 | 2012 |
| Imaging Microglial Activation in Untreated First-Episode Psychosis: A PET Study With [18F]FEPPA S Hafizi, HH Tseng, N Rao, T Selvanathan, M Kenk, RP Bazinet, ... American Journal of Psychiatry 174 (2), 118-124, 2017 | 136 | 2017 |
| Synaptic changes in Parkinson disease assessed with in vivo imaging D Matuskey, S Tinaz, KC Wilcox, M Naganawa, T Toyonaga, M Dias, ... Annals of neurology 87 (3), 329-338, 2020 | 133 | 2020 |
| In-vivo imaging of grey and white matter neuroinflammation in Alzheimer’s disease: a positron emission tomography study with a novel radioligand,[18F]-FEPPA I Suridjan, BG Pollock, N Verhoeff, AN Voineskos, T Chow, PM Rusjan, ... Molecular psychiatry 20 (12), 1579-1587, 2015 | 123 | 2015 |
| Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use R Mizrahi, M Kenk, I Suridjan, I Boileau, TP George, K McKenzie, ... Neuropsychopharmacology 39 (6), 1479-1489, 2014 | 97 | 2014 |
| Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO R Mizrahi, O Agid, C Borlido, I Suridjan, P Rusjan, S Houle, G Remington, ... Schizophrenia research 131 (1-3), 63-68, 2011 | 87 | 2011 |
| Elevated striatal dopamine function in immigrants and their children: a risk mechanism for psychosis A Egerton, OD Howes, S Houle, K McKenzie, LR Valmaggia, MR Bagby, ... Schizophrenia bulletin 43 (2), 293-301, 2017 | 82 | 2017 |
| Neuroinflammation in healthy aging: A PET study using a novel Translocator Protein 18 kDa (TSPO) radioligand,[18F]-FEPPA I Suridjan, PM Rusjan, AN Voineskos, T Selvanathan, E Setiawan, ... Neuroimage 84, 868-875, 2014 | 75 | 2014 |
| An accurate fully automated panel of plasma biomarkers for Alzheimer's disease S Palmqvist, E Stomrud, N Cullen, S Janelidze, E Manuilova, A Jethwa, ... Alzheimer's & Dementia 19 (4), 1204-1215, 2023 | 60 | 2023 |
| Dopamine response to psychosocial stress in chronic cannabis users: a PET study with [11C]-(+)-PHNO R Mizrahi, I Suridjan, M Kenk, TP George, A Wilson, S Houle, P Rusjan Neuropsychopharmacology 38 (4), 673-682, 2013 | 59 | 2013 |
| CSF synaptic biomarkers in the preclinical stage of Alzheimer disease and their association with MRI and PET: a cross-sectional study M Milà-Alomà, A Brinkmalm, NJ Ashton, H Kvartsberg, M Shekari, ... Neurology 97 (21), e2065-e2078, 2021 | 46 | 2021 |
| Dopamine response to psychosocial stress in humans and its relationship to individual differences in personality traits I Suridjan, I Boileau, M Bagby, PM Rusjan, AA Wilson, S Houle, R Mizrahi Journal of psychiatric research 46 (7), 890-897, 2012 | 42 | 2012 |
| Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task I Suridjan, P Rusjan, J Addington, AA Wilson, S Houle, R Mizrahi Journal of Psychiatry and Neuroscience 38 (2), 98-106, 2013 | 39 | 2013 |
| The application of positron emission tomography (PET) imaging in CNS drug development I Suridjan, RA Comley, EA Rabiner Brain imaging and behavior 13, 354-365, 2019 | 35 | 2019 |
| Nigral stress-induced dopamine release in clinical high risk and antipsychotic-naïve schizophrenia HH Tseng, JJ Watts, M Kiang, I Suridjan, AA Wilson, S Houle, PM Rusjan, ... Schizophrenia bulletin 44 (3), 542-551, 2018 | 34 | 2018 |
| Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer’s disease M Ruthirakuhan, N Herrmann, I Suridjan, EH Abraham, I Farber, ... Expert opinion on pharmacotherapy 17 (18), 2417-2429, 2016 | 32 | 2016 |
